- Home
- PPBT vs ACXP Comparison
PPBT vs ACXP Comparison
Compare PPBT & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PPBT | ACXP |
|---|---|---|
| Founded | 2010 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9M | 3.8M |
| IPO Year | 2014 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PPBT | ACXP |
|---|---|---|
| Price | $4.05 | $2.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $30.00 | ★ $95.50 |
| AVG Volume (30 Days) | 8.7K | ★ 1.3M |
| Earning Date | 05-20-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.41 | $0.29 |
| 52 Week High | $5.18 | $8.34 |
Technical Indicators
Market Signals| Indicator | PPBT | ACXP |
|---|---|---|
| Relative Strength Index (RSI) | 60.47 | 43.65 |
| Support Level | $3.63 | $2.48 |
| Resistance Level | $4.39 | $2.89 |
| Average True Range (ATR) | 0.30 | 0.39 |
| MACD | -0.09 | -0.21 |
| Stochastic Oscillator | 68.53 | 18.14 |
Price Performance
Historical ComparisonAbout PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage biotechnology company focused on the development and commercialization of pharmaceuticals. It currently have a preclinical tri-specific antibodies platform, CAPTN-3, with its therapeutic candidates, IM1240 and IM1305, and two other oncology therapeutic candidates that are in the clinical trial phase, CM24 and NT219, neither of which has been approved for marketing and are not being sold, marketed, or commercialized.
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.